ConductScience.org, home

Paper34846705

Consensus on the secondary prevention of primary liver cancer.

Nan Y and 11 others. Hepatol Int, 2021. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. Consensus on the secondary prevention of primary liver cancer. Papers, record 34846705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34846705

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Consensus on the secondary prevention of primary liver cancer.
PubMed
Journal
Hepatol Int
PubMed
Year
2021
PubMed
Publication types
Journal Article, Consensus Statement
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
0.75
iCite
Revised in PubMed
2026-05-18
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nan YYueminhttps://orcid.org/0000-0003-4192-099X
2Xu XXiaoyuan
3Gao YYanhang
4Wang RRongqi
5Li WWengang
6Yang MMing
7Liu LLingdi
8Duan ZZhongping
9Jia JJidong
10Wei LLai
11Zhuang HHui
12Chinese Society of Hepatology, Chinese Medical AssociationGroup

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
GastroenterologyMajor topic
Liver NeoplasmsMajor topic
Humans
Secondary Prevention

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in35020155Correction to: Consensus on the secondary prevention of primary liver cancer.https://conductscience.org/library/papers/35020155

Source PubMed

Download CSV of comments and corrections

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118436948GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.BMJ2008https://conductscience.org/library/papers/18436948PubMed
218483053Grading quality of evidence and strength of recommendations for diagnostic tests and strategies.BMJ2008https://conductscience.org/library/papers/18483053PubMed
333538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
425752327Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.Liver Int2015https://conductscience.org/library/papers/25752327PubMed
529395269
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.
Lancet2018https://conductscience.org/library/papers/29395269PubMed
628983565The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.JAMA Oncol2017https://conductscience.org/library/papers/28983565PubMed
726566246Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.Hepatology2016https://conductscience.org/library/papers/26566246PubMed
823041539Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.Clin Gastroenterol Hepatol2012https://conductscience.org/library/papers/23041539PubMed
929624699Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology2018https://conductscience.org/library/papers/29624699PubMed
1016391218Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA2006https://conductscience.org/library/papers/16391218PubMed
1110904089Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives.J Natl Cancer Inst2000https://conductscience.org/library/papers/10904089PubMed
1212124405Hepatitis B e antigen and the risk of hepatocellular carcinoma.N Engl J Med2002https://conductscience.org/library/papers/12124405PubMed
1318096267Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.J Hepatol2008https://conductscience.org/library/papers/18096267PubMed
1430871980Global liver disease burdens and research trends: Analysis from a Chinese perspective.J Hepatol2019https://conductscience.org/library/papers/30871980PubMed
1515918143Hepatocellular carcinoma: epidemiology, risk factors, and screening.Semin Liver Dis2005https://conductscience.org/library/papers/15918143PubMed
1610428733
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Ann Intern Med1999https://conductscience.org/library/papers/10428733PubMed
1719395111Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis.J Hepatol2009https://conductscience.org/library/papers/19395111PubMed
1823094699Risk stratification for hepatitis B virus related hepatocellular carcinoma.J Gastroenterol Hepatol2013https://conductscience.org/library/papers/23094699PubMed
1921995442How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature.BMC Cancer2011https://conductscience.org/library/papers/21995442PubMed
2015066364A meta-analysis of alcohol consumption and the risk of 15 diseases.Prev Med2004https://conductscience.org/library/papers/15066364PubMed

See all 52 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
42856947Artificial intelligence in hepatocellular carcinoma diagnosis and AI-assisted treatment support: Current landscape and future directions.Liver Res2026https://conductscience.org/library/papers/42856947PubMed
41654824Trend analysis of liver cancer mortality in Chinese residents from 2002 to 2021.BMC Cancer2026https://conductscience.org/library/papers/41654824PubMed
41582564Intravoxel Incoherent Motion Diffusion-weighted MR Imaging for Monitoring the Therapeutic Efficacy of Interventional Photothermal Therapy with Nanoparticles in Rabbit VX2 TumorsCurr Med Imaging2026https://conductscience.org/library/papers/41582564PubMed
41184938LEAST as a novel prediction model of hepatocellular carcinoma development in patients with chronic hepatitis B: a multi-center study.BMC Med2025https://conductscience.org/library/papers/41184938PubMed
39959031Physical activity and exercise in liver cancer.Liver Res2024https://conductscience.org/library/papers/39959031PubMed
38966543Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma.Front Pharmacol2024https://conductscience.org/library/papers/38966543PubMed
37568847Application of the Multi-Omics Liquid Biopsy Method M2P-HCC in Early Liver Cancer Screening for High-Risk Individuals with Hepatitis B-Related Liver Cancer.Diagnostics (Basel)2023https://conductscience.org/library/papers/37568847PubMed
37009320Prevention of malignant digestive system tumors should focus on the control of chronic inflammation.World J Gastrointest Oncol2023https://conductscience.org/library/papers/37009320PubMed
36924120The clinical management of hepatocellular carcinoma in China: Progress and challenges.Clin Mol Hepatol2023https://conductscience.org/library/papers/36924120PubMed
35498180Evaluation of Therapeutic Effects of Computed Tomography Imaging Classification Algorithm-Based Transcatheter Arterial Chemoembolization on Primary Hepatocellular Carcinoma.Comput Intell Neurosci2022https://conductscience.org/library/papers/35498180PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ACE1636PubTator's text mininghttps://conductscience.org/library/genes/1636NCBI Gene
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174NCBI Gene
F22147PubTator's text mininghttps://conductscience.org/library/genes/2147NCBI Gene
GPC32719PubTator's text mininghttps://conductscience.org/library/genes/2719NCBI Gene
SPP16696PubTator's text mininghttps://conductscience.org/library/genes/6696NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34846705

GET https://conductscience.org/api/papers/v1/34846705/references?page=2